Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5 billion (USD 211.95 million) to expand its manufacturing capabilities in Suzhou, a strategic move aimed at augmenting the production of drugs for type 2 diabetes and obesity. This capital expenditure is set to not only meet the growing demand within China but also accommodate the company’s future pipeline products, thereby reinforcing Lilly’s commitment to addressing chronic diseases in the region.
The investment, which is expected to create 120 high-quality jobs at the Suzhou facility, will also establish the site as a hub for exporting drugs to Europe, highlighting Lilly’s global manufacturing footprint and its ability to serve diverse markets. This expansion follows a remarkable increase in the global manufacturing capacity for Lilly’s intestinal glucagon injection drugs, which has doubled since 2022. – Flcube.com
